Group items tagged

Study to assess the efficacy of pantoprazole for the treatment of infants with symptomatic Gastroesophageal Reflux Disease (GERD)

Study is to evaluate the pharmacokinetics (blood levels), pharmacodynamics (how the drug acts on the body), and the safety of rabeprazole sodium for the treatment of gastroesophageal reflux disease (GERD) in new borns and pre-term infants (less than 44 weeks of age).

Purpose of this completed study is to provide additional information on safety and tolerability after multiple doses of pantoprazole in infants

Study to assess the development and neurological status of all children who were diagnosed as "mild ventriculomegaly" during the pregnancy in the last 6 years and to prospectively follow up all the children who will be diagnosed from the beginning of the study on for 6 years.

Study to promote research in the area of cerebral palsy by connecting researchers with persons with cerebral palsy through a secure, established database.

Abnormal Executive function (EF) profile was considered a major characteristic of Attention deficit / hyperactivity disorder (ADHD) and autism, and is frequently implicated in Developmental coordination disorder (DCD) children as well. This study is to characterize the profile of executive functions and eye movements in several populations of children with developmental disabilities.

The relation between eye movement and brain function is a subject of interest to the National Eye Institute. By comparing eye movement in healthy volunteers to research conducted on patients who have difficulty moving their eyes, the National Eye Institute hopes to develop and improve diagnostic procedures for people with eye diseases. Objectives: To study eye movement in 100 healthy adult and child volunteers. To understand how individuals see visual patterns and how eye movement affects the ability to see.

AHRQ Research and Quality Evidence Report and Technology Assessment: Number 72 - Failure to Thrive - Criteria for Determining disability in Infants and Children summary.The Social Security Administration (SSA) requested that the Agency for Healthcare Research and Quality (AHRQ), through its Evidence-based Practice Center (EPC) program, provide a systematic review of the scientific evidence on whether children, defined by investigators as failing to thrive or grow adequately, have a concurrent disability, or will have one within 6 months. The population of interest includes children age 18 years or younger, both male and female, of all racial, ethnic, and socioeconomic groupings. The evidence report was prepared to assist SSA in updating its Listing of Impairments and revising its disability policy, as may be appropriate.

The Agency for Healthcare Research and Quality (AHRQ) is the health services research arm of the U.S. Department of Health and Human Services (HHS), complementing the biomedical research mission of its sister agency, the National Institutes of Health. AHRQ is a home to research centers that specialize in major areas of health care research such as quality improvement and patient safety, outcomes and effectiveness of care, clinical practice and technology assessment, and health care organization and delivery systems. Source of funding and technical assistance for health services research and research training at leading U.S. universities and other institutions, as well as a science partner, working with the public and private sectors to build the knowledge base for what works-and does not work-in health and health care and to translate this knowledge into everyday practice and policymaking.

Study to evaluate the effects of pre-operative gait analysis testing on surgical outcomes in children with cerebral palsy who have problems walking.

Vanderbilt study is to determine the safe and effective levels of optical stimulation in peripheral nerves of humans otherwise undergoing nerve lesioning in surgery, namely children undergoing selective rhizotomy for treatment of medically refractory spasticity.

Study to investigate if patients who have had a stroke and suffer from spasticity might benefit from being given BOTOX® in addition to the normal Standard Care. Spasticity is characterized by stiffness or frequent cramps accompanied by pain and abnormal movements and can prevent the carrying out of everyday tasks such as walking and getting dressed. BOTOX® is a neurotoxin, which is used to prevent the contraction of muscle fibre and has been shown to reduce spasticity significantly. Patients will be enrolled in this study at about 33 locations in Europe and Canada

Completed observational study assessed whether measurements of certain pro-inflammatory and anti-inflammatory cytokines in the blood (either singly or in combination) at birth and/or up to day of life 21 can predict cerebral palsy at 18-22 months corrected age.

Study is to determine whether nerve growth factor (cerebrolysin®) therapy will improve the psychomotor outcome in infants with moderate and severe hypoxic ischemic encephalopathy.

The Johns Hopkins School of Medicine's Brain Science Institute (BSi) brings together both basic and clinical neuroscientists from across the Johns Hopkins campuses. The BSi represents one of the largest and most diverse groups in the University. The goals of our research is to foster new programs in basic neuroscience discovery, initiate a translational research program that will develop new treatments for brain-based diseases and encourage collaboration, interdisciplinary teams, and new thinking that will have a global influence on research and treatment of the nervous system.

Study of effects of prenatal nicotine exposture by the Instatute of Psychiatry, King's College London. Study design provides a model for the impact of prenatal exposure to nicotine at blood levels comparable with those in medium and heavy smokers. There were marked developmental and behavioural deficits induced in the offspring of nicotine-exposed female rats